Pharmacological induction of leukotriene B4-12-hydroxydehydrogenase suppresses the oncogenic transformation of human hepatoma HepG2 cells

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 735-745

  Wei, Lai ^a   Liu, Jie ^b   Le, X Chris ^b   Han, Yifan ^c   Tong, Yao ^a   Lau, Allan S Y ^d   Rong, Jianhui ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bioactivity guided fractionation; Cell cycle arrest; Chemoprevention; Gallic acid; Leukotriene B4; Leukotriene B4 12 hydroxydehydrogenase; Oncogenic transformation; Radix astragali; Radix paeoniae rubra

Indexed keywords

ASTRAGALIN; GALLIC ACID; HERBACEOUS AGENT; PAEONIA RADIX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HEPG2; CELL TRANSFORMATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; GENE INDUCTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOTRIENE B4 12 HYDROXYDEHYDROGENASE GENE; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALCOHOL OXIDOREDUCTASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INDUCTION; HEP G2 CELLS; HUMANS; PAEONIA; PLANT EXTRACTS; TRANSFECTION;

EID: 79959949258     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1082     Document Type: Article

References (60)

1. Samuelsson B and Claesson HE: Leukotriene B4 biosynthesis and role in lymphocytes. Adv Prostaglandin Thromboxane Leukot Res 20: 1-13, 1990.
2. Yokomizo T, Izumi T and Shimizu T: Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 385: 231-241, 2001.
3. Bittner S and Wielckens K: Glucocorticoid-induced lymphoma cell growth inhibition: the role of leukotriene B4 Endocrinology 123: 991-1000, 1988.
4. Yokomizo T, Kato K, Terawaki K, Izumi T and Shimizu T: A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192: 421-432, 2000.
5. Avis IM, Jett M, Boyle T, et al: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97: 806-813, 1996. (Pubitemid 26057100)
6. Chen X, Li N, Wang S, et al: Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst 95: 1053-1061, 2003. (Pubitemid 36950109)
7. Kato K, Yokomizo T, Izumi T and Shimizu T: Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. J Exp Med 192: 413-420, 2000. (Pubitemid 30629166)
8. Earashi M, Noguchi M and Tanaka M: In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 37: 29-37, 1996.
9. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H and Nakajima A: Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 103: 24-32, 2007. (Pubitemid 46175592)
10. Tai HH, Ensor CM, Tong M, Zhou H and Yan F: Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 68-69: 483-493, 2002.
11. Dick RA, Kwak MK, Sutter TR and Kensler TW: Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase. J Biol Chem 276: 40803-40810, 2001.
12. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ and Hansson GK: Leukotriene B4 signaling through NF-kappaB-dependent BLTl receptors on vascular smooth muscle cells in athero-sclerosis and intimai hyperplasia. Proc Natl Acad Sci USA 102: 17501-17506, 2005. (Pubitemid 41740895)
13. Radmark O, Shimizu T, Jornvall H and Samuelsson B: Leukotriene A4 hydrolase in human leukocytes. Purification and properties. J Biol Chem 259: 12339-12345, 1984. (Pubitemid 15204805)
14. Tong M, Ding Y and Tai HH: Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis 27: 2170-2179, 2006. (Pubitemid 44644805)
15. Yan M, Rerko RM, Platzer P, et al: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004. (Pubitemid 39657428)
16. Wolf I, O'Kelly J, Rubinek T, et al: 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66: 7818-7823, 2006. (Pubitemid 44289243)
17. Zhao Y, Weng CC, Tong M, Wei J and Tai HH: Restoration of leukotriene B(4)-12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo. Lung Cancer 68: 161-169, 2010.
18. Primiano T, Li Y, Kensler TW, Trush MA and Sutter TR: Identi cation of dithiolethione-inducible gene-1 as a leukotriene B4 12-hydroxydehydrogenase: implications for chemoprevention. Carcinogenesis 19: 999-1005, 2008.
19. Efferth T, Kahl S, Paulus K, et al: Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther 7: 152-161, 2008.
20. Galati G and O'Brien PJ: Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med 37: 287-303, 2004. (Pubitemid 38833996)
21. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
22. Zhan LY, Xia ZY, Chen C and Wang XY: Effect of Radix Paeoniae Rubra on the expression of HO-1 and iNOS in rats with endotoxin-induced acute lung injury. Chin J Traumatol 9: 181-186, 2006. (Pubitemid 43862963)
23. Liu EH, Qi LW, Li B, et al: High-speed separation and characterization of major constituents in Radix Paeoniae Rubra by fast high-performance liquid chromatography coupled with diode-array detection and time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 23: 119-130, 2009.
24. Cui R, He J, Wang B, et al: Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother Pharmacol 51: 75-80, 2003. (Pubitemid 36057026)
25. Sinclair S: Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev 3: 338-344, 1998.
26. Wong BY, Lau BH, Tadi PP and Teel RW: Chinese medicinal herbs modulate mutagenesis, DNA binding and metabolism of aflatoxin B1. Mutat Res 279: 209-216, 1992.
27. Rios J and Waterman P: A review of the pharmacology and toxicology of Astragalus. Phytother Res 11: 411-418, 1997.
28. Rong J, Tilton R Shen J, et al: Genome-wide biological response fingerprinting (BioReF) of the Chinese botanical formulation ISF-1 enables the selection of multiple marker genes as a potential metric for quality control. J Ethnopharmacol 113: 35-44, 2007. (Pubitemid 47082498)
29. Qi H, Siu SO, Chen Y, et al: Senkyunolides reduce hydrogen peroxide-induced oxidative damage in human liver HepG2 cells via induction of heme oxygenase-1. Chem Biol Interact 183: 380-389, 2010.
30. Rong JH, Cheung CYH, Lau ASY, Shen JG, Tarn PKH and Cheng YC: Induction of heme oxygenase-1 by traditional Chinese medicine formulation ISF-. and its ingredients as a cytoprotective mechanism against oxidative stress. Int J Mol Med 21: 405-411, 2008.
31. Lu J, Wei Y and Yuan Q: Preparative separation of gallic acid from Chinese traditional medicine by high-speed counter-current chromatography and followed by preparative liquid chromatography. Separation Purification Technol 55: 40-43, 2007. (Pubitemid 46497861)
32. Xu S, Yang L, Tian R, et al: Species differentiation and quality assessment of Radix Paeoniae Rubra (Chi-shao) by means of high-performance liquid chromatographic fingerprint. J Chromatogr A 1216: 2163-2168, 2009.
33. Wang LH: Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 71: 361-367, 2004.
34. 2 level in GC-1 spg cells. Toxicol In Vitro 22: 159-163, 2008. (Pubitemid 350267114)
35. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E and Moreno-Sanchez R: The causes of cancer revisited: 'mitochondrial malignancy' and ROS-induced oncogenic trans-formation - why mitochondria are targets for cancer therapy. Mol Aspects Med 31: 145-170, 2010.
36. Schinzel AC and Hahn WC: Oncogenic transformation and experimental models of human cancer. Front Biosci 13: 71-84, 2008. (Pubitemid 351594764)
37. Colotta F: Anticancer drug discovery and development. Adv Exp Med Biol 610: 19-42, 2008.
38. Powis G: Signalling pathways as targets for anticancer drug development. Pharmacol Ther 62: 57-95, 1994.
39. Martinez JD: Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy. Future Oncol 6: 1857-1862, 2010.
40. Kensler TW, Curphey TJ, Maxiutenko Y and Roebuck BD: Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. Drug Metabol Drug Interact 17: 3-22, 2000. (Pubitemid 32047530)
41. Boik J: Natural Compounds in Cancer Therapy. Oregon Medical Press, 2001.
42. Efferth T, Li PC, Konkimalla VS and Kaina B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 13: 353-361, 2007. (Pubitemid 47126989)
43. Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007. (Pubitemid 46595760)
44. Granneman S and Baserga SJ: Crosstalk in gene expression: coupling and co-regulation of rDNA transcription, pre-ribosome assembly and pre-rRNA processing. Curr Opin Cell Biol 17 281-286, 2005. (Pubitemid 40719918)
45. Doppler W, Geymayer S and Weirich HG: Synergistic and antagonistic interactions of transcription factors in the regulation of milk protein gene expression. Mechanisms of cross-talk between signalling pathways. Adv Exp Med Biol 480: 139-146, 2000. (Pubitemid 32177790)
46. Lee DC, Yang CL, Chik SC, et al: Bioactivity-guided identification and cell signaling technology to delineate the immunomodulatory effects of Panax ginseng on human promonocytic U937 cells. J Transi Med 7: 34, 2009.
47. Kroes BH, van den Berg AJ, Quarles van Ufford HC, van Dijk H and Labadie RP: Anti-inflammatory activity of gallic acid. Planta Med 58: 499-504, 1992. (Pubitemid 23074535)
48. Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y and Yabu Y: Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. Biochem Biophys Res Commun 204: 898-904, 1994. (Pubitemid 24344005)
49. Sarkaria JN, Busby EC, Tibbetts RS, et al: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382, 1999. (Pubitemid 29418757)
50. Faried A, Kurnia D, Faried LS, et al: Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int J Oncol 30: 605-613, 2007.
51. Dodo K, Minato T, Noguchi-Yachide T, Suganuma M and Hashimoto Y: Antiproliferative and apoptosis-inducing activities of alkyl gallate and gallamide derivatives related to (-)-epigallocatechin gallate. Bioorg Med Chem 16: 7975-7982, 2008.
52. Ahn EY, Jiang Y, Zhang Y, et al: Cytotoxicity of p-tyrosol and its derivatives may correlate with the inhibition of DNA replication initiation. Oncol Rep 19: 527-534, 2008. (Pubitemid 351176116)
53. Isuzugawa K, Ogihara Y and Inoue M: Different generation of inhibitors against gallic acid-induced apoptosis produces different sensitivity to gallic acid. Biol Pharm Bull 24: 249-253, 2001. (Pubitemid 32237162)
54. Kuo PL, Hsu YL, Sung SC, Ni WC, Lin TC and Lin CC: Induction of apoptosis in human breast adenocarcinoma MCF-7 cells by pterocarnin A from the bark of Pterocarya stenoptera via the Fas-mediated pathway. Anticancer Drugs 18: 555-562, 2007.
55. Miyamoto Y, Haylor JL and El Nahas AM: Cellular toxicity of catechin analogues containing gallate in opossum kidney proximal tubular (OK) cells. J Toxicol Sci 29: 47-52, 2004. (Pubitemid 38405097)
56. Sohi K, Mittal N, Hundal M and Khanduja K: Gallic acid an antioxidant, exhibits anti-apoptotic potential in normal human lymphocytes: a Bcl-2 independent mechanism. J Nutr Sci Vitaminol 49: 221-227, 2003. (Pubitemid 37129111)
57. Agarwal C, Tyagi A and Agarwal R: Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther 5: 3294-3302, 2006. (Pubitemid 46092073)
58. Niho N, Shibutani M, Tamura T, et al: Subchronic toxicity study of gallic acid by oral administration in F344 rats. Food Chem Toxicol 39: 1063-1070, 2001. (Pubitemid 32778624)
59. Cai G, Liu B, Liu W, et al: Buyang Huanwu Decoction can improve recovery of neurological function, reduce infarction volume, stimulate neural proliferation and modulate VEGF and Flk1 expressions in transient focal cerebral ischaemic rat brains. J Ethnopharmacol 113: 292-299, 2007. (Pubitemid 47239253)
60. Zhang X, Xu LS, Wang ZQ, et al: ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 570: 7-12, 2004. (Pubitemid 38900947)